Bordetella pertussis fimbriae are effective carrier proteins in Neisseria meningitidis serogroup C conjugate vaccines

FEMS Immunology and Medical Microbiology

Volumn 31, Issue 2, 2001, Pages 153-162

  Reddin, Karen M ^a   Crowley Luke, Annette ^a   Clark, Simon O ^a   Vincent, Philip J ^a   Gorringe, Andrew R ^a   Hudson, Michael J ^a   Robinson, Andrew ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Bordetella pertussis fimbria; Carrier protein; Conjugate vaccine; Neisseria meningitidis

Indexed keywords

CARRIER PROTEIN; DIPHTHERIA TOXOID; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; CONJUGATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIMBRIA; GEL PERMEATION CHROMATOGRAPHY; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROTECTION; SEROTYPE; STRAIN DIFFERENCE; TECHNIQUE; THYMUS; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIMBRIAE, BACTERIAL; LUNG; MENINGITIS, MENINGOCOCCAL; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; TRACHEA; VACCINES, CONJUGATE;

EID: 0034838408     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(01)00254-1     Document Type: Article

References (43)

1. Human immunity to the meningococcus I. The role of humoral antibodies
2. Human immunity to the meningococcus IV. Immunogenicity of group A and group C polysaccharides in human volunteers
3. Bactericidal antibody after colonisation with Neisseria meningitidis
4. Human immunity to the meningococcus II. Development of natural immunity
5. Thymus-independent and thymus-dependent responses to polysaccharide antigens
6. Murine immune response to Neisseria meningitidis group C capsular polysaccharide: Analysis of monoclonal antibodies generated in response to a thymus dependent toxoid conjugate vaccine
7. Epidemiological impact of conjugate vaccines against invasive disease caused by H. influenzae type b
8. Safety, immunogenicity, and induction of immunological memory by a serogroup C meningococcal conjugate vaccine in infants: A randomised controlled trial
9. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
10. Preparation and immunochemical characterisation of meningococcal serogroup C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines
11. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy
12. Antibody response to Hib and dp toxin induced by conjugate of oligosaccharide of the type b capsule with the non-toxic protein CRM197
13. Recent developments in bacterial conjugate vaccines
14. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines
15. Randomised control trial of two-component, three-component, and five component acellular pertussis vaccine
16. Formulation and characterisation of Bordetella pertussis fimbriae as novel carrier proteins for Hib conjugate vaccines
17. Serospecific protection of mice against intranasal infection with Bordetella pertussis
18. Development of polysaccharide vaccines for the prevention of meningococcal diseases
19. Effects of guanidinium hydrochloride on the structure and immunological properties of Bordetella pertussis fimbriae
20. Preparation, characterisation, and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates
21. Mechanism of the reaction of imidoesters with amines
22. Molecular size characterisation of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines
23. Monosaccharides - The Warren assay for sialic acid
24. Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod
25. A modified enzyme-linked immunosorbent assay of measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses
26. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardised enzyme-linked immunosorbent assay
27. Standardisation and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays
28. Periplasmic superoxide dismutase in meningococcal pathogenicity
29. Comparison of the induction of IgM and IgG antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates
30. Immunogenicity in infants of Hib polysaccharide in a conjugate vaccine with Neisseria meningitidis outer membrane protein
31. Immunochemistry of groups A, B and C meningococcal polysaccharide-tetanus toxoid conjugates
32. T cell modulation of the murine antibody response to Neisseria meningitidis group A capsular polysaccharide
33. Vaccines for the prevention of meningococcal disease
34. Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide
35. Carrier-induced epitopic suppression, a major issue for synthetic vaccines
36. Effect of carrier priming on immunogenicity of saccharide-protein conjugate
37. Epitopic specific regulation I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses
38. Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. I. Ontogeny
39. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine
40. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate
41. The history of pertussis vaccination: From whole-cell to subunit vaccines. Vaccinia, vaccination, vaccinology. Jenner, Pasteur and their successors